Action required: Please refresh your browser
We have recently implemented some changes that require a hard refresh of your browser: Please hold down the CTRL-key and press the F5 key.
After a successful hard refresh, this message should not appear anymore.
More details about this topic are available here »
ASLAN Pharmaceuticals Enrolls First Subject in Phase 1 Study for ASLAN004 in Atopic Dermatitis | ||||
By: Nasdaq / GlobeNewswire - 17 Oct 2018 | Back to overview list |
|||
SINGAPORE, Oct. 18, 2018 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (ASLAN, 6497.TT, Nasdaq: ASLN), a clinical-stage biopharmaceutical company targeting cancers that are both highly prevalent in Asia and orphan indications in the United States and Europe, today announced the enrolment of the first subject in a phase 1 study investigating ASLAN004 as a therapeutic antibody for atopic dermatitis. The phase 1 trial is the first clinical study of ASLAN004 and will be conducted in Singapore, Australia and the United States. The single ascending dose portion of the study will recruit healthy volunteers and the multiple ascending dose component will recruit moderate to severe atopic dermatitis patients. The single ascending dose study is expected to complete in the first half of 2019. ASLAN004 is a fully human monoclonal antibody that targets the IL-13 receptor ?1 subunit (IL-13R?1) and has demonstrated inhibition of interleukin 4 (IL-4) and interleukin 13 (IL-13) in preclinical investigations. IL-4 and IL-13 are central to triggering symptoms of atopic dermatitis, such as redness and itching of the skin. By targeting IL-13R?1, ASLAN004 has the potential to offer both a lower dose and dosing frequency than currently available treatments for moderate to severe atopic dermatitis which target the same pathways. The selective binding of ASLAN004 may also offer a more favourable side effect profile. Dr Mark McHale, COO of ASLAN Pharmaceuticals, said: “Initiating this study is an important step for ASLAN that marks the first time the ASLAN team has taken a development programme from preclinical to first in man studies. ASLAN004 has the potential to address a significant unmet medical need as a best-in-class therapy for patients with moderate to severe atopic dermatitis worldwide. This study will enable us to investigate its potential to offer more selective binding, improved tolerability, and greater convenience with reduced injection frequency than current treatment options.” Atopic dermatitis is the most common dermatological disease, affecting over 200 million patients worldwide1, characterised by red inflamed skin and severe daytime and night time itching, which can severely impact patients’ quality of life. In the US, it is estimated that AD occurs in 7.3% of US adults2. Currently available therapeutics are limited and management is challenging in the majority of cases. Media and IR contacts
About ASLAN004 About ASLAN Pharmaceuticals Forward looking statements All statements other than statements of historical fact are forward-looking statements. The words “believe,” “may,” “might,” “could,” “will,” “aim,” “estimate,” “continue,” “anticipate,” “intend,” “expect,” “plan,” or the negative of those terms, and similar expressions that convey uncertainty of future events or outcomes are intended to identify estimates, projections and other forward-looking statements. Estimates, projections and other forward-looking statements speak only as of the date they were made, and, except to the extent required by law, the Company undertakes no obligation to update or review any estimate, projection or forward-looking statement. ________________________ |
||||
|
||||
Copyright 2018 Nasdaq / GlobeNewswire | Back to overview list |